Holen Sie sich die Stockscreener-App
19.30
3.60%
0.67
Handel nachbörslich:
19.30
Schlusskurs vom Vortag:
$18.63
Offen:
$18.85
24-Stunden-Volumen:
1.39M
Relative Volume:
0.80
Marktkapitalisierung:
$1.96B
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-6.6782
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
+6.87%
1M Leistung:
-1.28%
6M Leistung:
+46.43%
1J Leistung:
-1.08%
1-Tages-Spanne:
$18.64
$19.34
1-Wochen-Bereich:
$16.98
$19.92
52-Wochen-Spanne:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.30 | 1.89B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Morgan Stanley Upgrades Nurix Therapeutics (NRIX) - Nasdaq
How Nurix Therapeutics Inc. stock compares to market leadersShare Buyback & Trade Opportunity Analysis - ulpravda.ru
Will Nurix Therapeutics Inc. stock beat EPS estimates2025 Major Catalysts & Precise Swing Trade Entry Alerts - ulpravda.ru
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpStill a Buy? - MarketBeat
Why Nurix Therapeutics Inc. stock appeals to analystsJuly 2025 Recap & Fast Moving Stock Trade Plans - ulpravda.ru
What 18 Analyst Ratings Have To Say About Nurix Therapeutics - Benzinga
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Yahoo Finance
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Insider Monkey
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance
Should I hold or sell Nurix Therapeutics Inc. stock in 20252025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Stock Analysis: Is Nurix Therapeutics Inc. stock a defensive play in 2025Quarterly Performance Summary & AI Forecasted Entry and Exit Points - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Does New NX-5948 Phase 2 Dose Selection Change The Bull Case For Nurix Therapeutics (NRIX)? - simplywall.st
Is Nurix Therapeutics Inc. stock a defensive play in 2025Index Update & Stepwise Entry/Exit Trade Alerts - Улправда
Will Nurix Therapeutics Inc. stock gain from lower inflationEarnings Trend Report & Reliable Price Breakout Alerts - Улправда
Sell Signal: Is Nurix Therapeutics Inc. stock a defensive play in 2025 - Улправда
Nurix Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
Officer Ring Sells 3,760 ($67.3K) Of Nurix Therapeutics Inc [NRIX] - TradingView — Track All Markets
Nurix Therapeutics (NRIX) Chief Legal Officer reports option exercise and stock sales - Stock Titan
Why Nurix Therapeutics Inc. stock could outperform in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4%Here's What Happened - MarketBeat
Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients - TipRanks
Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Given New $30.00 Price Target at Wells Fargo & Company - MarketBeat
Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025 - ts2.tech
Nurix Therapeutics, Inc. $NRIX Shares Purchased by Nikko Asset Management Americas Inc. - MarketBeat
Redmile Group LLC Lowers Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Optimistic Investors Push Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Up 48% But Growth Is Lacking - 富途牛牛
Nurix prices 24.5M shares at $10.21 in underwritten registered offering - MSN
Nurix Therapeutics price target raised to $31 from $28 at HC Wainwright - MSN
Cathie Wood Reduces Iridium Holdings While Adding Biotech Stock Nurix Therapeutics - parameter.io
Why Cathie Wood Just Sold Millions in Iridium and Bought This Biotech Stock - CoinCentral
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday - Investing.com
What insider trading reveals about Nurix Therapeutics Inc stockMarket Activity Report & Risk Controlled Daily Plans - moha.gov.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 at Mizuho - MarketBeat
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):